Astrazeneca (AZN) Other Non-Current Assets (2011 - 2025)

Astrazeneca's Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $559.0 million for Q4 2025.

• In Q4 2025, Other Non-Current Assets rose 57.02% year-over-year to $559.0 million; the TTM figure through Dec 2025 stood at $559.0 million (up 57.02% YoY), while the FY2025 annual figure was $559.0 million, up 57.02% from the prior year.
• Other Non-Current Assets was $559.0 million for Q4 2025 at Astrazeneca, up from $356.0 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $559.0 million in Q4 2025 to a low of -$447.0 million in Q1 2021.
• Historically, Other Non-Current Assets has averaged $229.3 million across 5 years, with a median of $315.0 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Other Non-Current Assets slumped 557.47% in 2021, then jumped 57.02% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $391.0 million in 2021, then tumbled by 37.85% to $243.0 million in 2022, then gained by 12.76% to $274.0 million in 2023, then grew by 29.93% to $356.0 million in 2024, then surged by 57.02% to $559.0 million in 2025.
• The last three Other Non-Current Assets figures came in at $559.0 million (Q4 2025), $356.0 million (Q4 2024), and $274.0 million (Q4 2023), per Business Quant data.